DNLI Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Denali Therapeutics (DNLI) has recently faced a setback with its Phase 2/3 HEALEY ALS Platform Trial for DNL343, which failed to meet primary efficacy endpoints. Despite this, analysts remain optimistic about the company's pipeline, particularly Tividenofusp alfa for Hunter syndrome, with a potential FDA filing imminent.
Technical Indicators:
- RSI (14): 33.45, indicating oversold conditions.
- MACD: Bearish crossover with a value of -1.71.
- SMA: Trading below 20, 50, and 200-day moving averages.
- Fibonacci Levels: Resistance at $16.67 and support at $14.41.
Price Action:
The stock closed at $15.50 on March 17, near the lower end of the Fibonacci range, suggesting potential testing of support levels.
Conclusion:
Given the mixed technical signals and recent trial failure, DNLI is expected to trade between $14.41 and $16.67 next week. The bearish trend and trial setback suggest a cautious stance.
Recommendation: Sell or hold DNLI in the next trading week.
DNLI Similar Chart Price Prediction
The price of DNLI is predicted to go up 13.53%, based on the high correlation periods with CVGI. The similarity of these two price pattern on the periods is 98.65%.
DNLI
CVGI
Up: 13.53%Similarity: 98.65%
DNLI Revenue Forecast
DNLI EPS Forecast
DNLI FAQs
What is DNLI revenue forecast for next quarter？
What is DNLI eps forecast for next quarter？
DNLI Analyst's Forecast
Matthew Harrison
Morgan Stanley
Buy
2025-03-07
Price Target
$41 → $33
Upside
+97.72%
Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics with an Overweight rating and a price target of $33, down from $41. The firm views Denali as "a key beneficiary" in an evolving landscape following FDA recognition of elevated heparan sulfate as a surrogate endpoint and models $359M in unadjusted sales for Tividenofusp Alfa in Hunter disease and $646M in unadjusted sales for DNL126 for Sanfilippo disease.
Mayank Mamtani
B. Riley Securities
Strong Buy
2025-03-05
Price Target
$38 → $35
Upside
+114.72%
Jay Olson
Oppenheimer
Buy
2025-03-03
Price Target
$50 → $42
Upside
+176.32%
